Study to Evaluate Mavacamten in Adults with Symptomatic

Recruiting

19 years - 99 years

All

Phase 3

20 participants needed

1 Location

Brief description of study

The purpose of this study is to compare the effects of the study drug versus a placebo on reducing the number of septal reduction therapy procedures performed in patients with symptomatic oHCM.

Detailed description of study

The purpose of this study is to compare the effects of the study drug versus a placebo on reducing the number of septal reduction therapy procedures performed in patients with symptomatic oHCM.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Septal Reduction Therapy
Age: 19 years - 99 years
Gender: All

Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

Updated on 04 Aug 2024. Study ID: 842832

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

Brief description of study

Detailed description of study

Eligibility of study

Find a site

Interested in the study